Strategic Immunoassay Portfolio Expansion

About QuidelOrtho

QuidelOrtho is a pure-play diagnostics leader with an 80+ year combined legacy, formed via a $6 billion merger in 2022. Its mission is to provide vital health information across the entire care continuum by leveraging a diversified technology portfolio spanning immunoassay, clinical chemistry, molecular diagnostics, and transfusion medicine. The company's strategy is to drive growth through portfolio integration, operational efficiency, and expanding its high-value informatics and service offerings to become an indispensable partner to healthcare providers globally.

Therapeutic Areas